drugset / Trial / NCT00361868

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

NCT00361868

Phase 3 Terminated 88 enrolled Solvay Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on glycemic control is not inferior to that of rosiglitazone and the efficacy of FC of fenofibrate and metformin on triglyceride control is superior to that of rosiglitazone.

Timeline

Start
2006-06
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fenofibrate Small molecule 54 mg Oral
Subject Metformin Small molecule 850 mg Oral
Comparator Rosiglitazone Small molecule 4 mg Oral